Patents by Inventor Kendall M. Mohler

Kendall M. Mohler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30L
    Publication number: 20080213259
    Abstract: The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Application
    Filed: August 16, 2007
    Publication date: September 4, 2008
    Applicant: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 7273609
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 7122183
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: October 17, 2006
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating rheumatoid arthritis using IL-17 antagonists
    Patent number: 6793919
    Abstract: A method of treating a mammal afflicted with rheumatoid arthritis by administering to the mammal an antibody that binds IL-17R is disclosed.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: September 21, 2004
    Assignee: Immunex Corporation
    Inventor: Kendall M. Mohler
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Publication number: 20040076626
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Application
    Filed: August 26, 2003
    Publication date: April 22, 2004
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 6652854
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: November 25, 2003
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • Methods for treating rheumatoid arthritis using IL-17 antagonists
    Publication number: 20020136724
    Abstract: A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.
    Type: Application
    Filed: October 18, 2001
    Publication date: September 26, 2002
    Inventor: Kendall M. Mohler
  • Methods for treating IL-18 mediated disorders
    Publication number: 20020098185
    Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody.
    Type: Application
    Filed: January 18, 2002
    Publication date: July 25, 2002
    Inventors: John E. Sims, Kendall M. Mohler, Teresa L. Born
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Publication number: 20020064527
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Application
    Filed: August 3, 2001
    Publication date: May 30, 2002
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke